Background: Case reports have related the use of HMG-CoA reductase inhibitors ('statins')
to Parkinson's disease (PD). Paradoxically, however, statins may have potentially beneficial …

The aim of the present work was to shed light on the role played by the
isoprenoid/cholesterol biosynthetic pathway in the modulation of emotional reactivity and …

METHODS Thirty-nine SD rats from the Department of Physiology vivarium aged between 5
and 6 months and with initial weights of 220-280 g were used for the tests. The study was …

Background & aim Schizophrenia is a chronic, disabling neurological illness. This study
investigated the effect of rosuvastatin (RSU) addition to the antipsychotic drug: olanzapine …

Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of the
pigmented dopaminergic neurons in the substantia nigra pars compacta with subsequent …

Background: Parkinson disease (PD) is the second most common neuro-degenerative
disease and the number of affected patients is growing. Until now, information on either risk …

The present study aims to directly investigate the behavioral and antioxidant effects of
simvastatin in a model of bipolar mania induced by lisdexamfetamine dimesylate. Wistar rats …

Simvastatin is a lipid-lowering agent that blocks the production of cholesterol through
inhibition of 3-hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase. In addition …

Statins are increasingly being used for the treatment of a variety of conditions beyond their
original indication for cholesterol lowering. We previously reported that simvastatin affected …

Primary or idiopathic Parkinson's disease (PD) is the second most common late-onset
neurodegenerative disease, characterized by several clinical features, such as resting …